Cindy Perettie is the Head of Molecular Lab Solutions. Prior to that she was at Foundation Medicine starting in February 2019 as its Chief Executive Officer. Ms. Perettie is passionate about improving the care of cancer patients and brings more than two decades of scientific and commercial experience with global biopharmaceutical organizations.
Prior to joining Foundation Medicine, Ms. Perettie served as senior vice president in global oncology product strategy for Roche’s Oncology unit, where she led one of the largest global oncology portfolios in the industry. Ms. Perettie began her tenure at Genentech as a program team leader for Avastin, and she led several successful therapy launches in the U.S. and abroad for Roche and Genentech across the oncology portfolio.. Since joining in 2004, she held roles of increasing responsibility at Genentech, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development. In 2012, Ms. Perettie took a hiatus from Genentech to join Sarah Cannon Research Institute (SCRI) as President, Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. During her tenure, she was responsible for leading and growing SCRI’s contract research organization globally, driving critical oncology clinical trials to further expand options for cancer patients and access precision medicine.
Before joining Genentech, Ms. Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corporation. Her pharmaceutical experience began as a research scientist associate director role at Chiron Corporation. She started her career as a senior research associate at Johns Hopkins University.